Department of Microbiology, Royal Hampshire County Hospital, Romsey Road, Winchester, UK.
J Antimicrob Chemother. 2011 May;66 Suppl 4:iv7-iv15. doi: 10.1093/jac/dkr072.
Linezolid has been widely used in the treatment of Gram-positive infections for more than a decade. It is unique amongst antibiotics active against most multiply-resistant Gram-positive bacteria in that there is an oral preparation with 100% bioavailability and an extensive volume of distribution. This review examines pharmacokinetic data relating to linezolid use in different patient groups (obesity, enteral feeding, renal failure, neonates, and paediatrics) and in different clinical conditions (sepsis syndrome, skin and soft tissue infection, diabetic foot infection, pneumonia, bone and joint infection, infection of the central nervous system, eye infection, and neutropenic sepsis).
利奈唑胺在治疗革兰氏阳性感染方面已经有十多年的广泛应用。与大多数针对多重耐药革兰氏阳性菌的抗生素不同，它具有口服制剂且 100%生物利用度和广泛的分布容积。这篇综述检查了与利奈唑胺在不同患者群体（肥胖、肠内喂养、肾衰竭、新生儿和儿科）和不同临床情况下（败血症综合征、皮肤和软组织感染、糖尿病足感染、肺炎、骨和关节感染、中枢神经系统感染、眼部感染和中性粒细胞减少性败血症）使用相关的药代动力学数据。
